These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23194788)

  • 1. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome.
    Luo J; Li J; Shen X; Hu X; Fang Z; Lv X; Zhou S
    Int J Cardiol; 2013 Sep; 167(5):2350-3. PubMed ID: 23194788
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
    Gao Y; Jia ZM; Sun YJ; Zhang ZH; Ren LN; Qi GX
    Chin Med J (Engl); 2012 Jul; 125(13):2250-4. PubMed ID: 22882843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
    Ko YG; Won H; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Bae JH; Lee S; Lim DS; Jang Y
    Am J Cardiol; 2014 Jul; 114(1):29-35. PubMed ID: 24831577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Patti G; Leoncini M; Toso A; Maioli M; Grieco D; Colonna G; Bellandi F; Di Sciascio G
    Int J Cardiol; 2014 Jun; 174(2):440-1. PubMed ID: 24767765
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
    Veselka J; Hájek P; Tomašov P; Tesař D; Brůhová H; Matějovič M; Branny M; Studenčan M; Zemánek D
    Am J Cardiol; 2014 Feb; 113(3):446-51. PubMed ID: 24304551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
    Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
    Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Oh SK; Rhee SJ; Yoo NJ; Kim NH; Jeong JW
    Int J Cardiol; 2011 Jan; 146(1):68-72. PubMed ID: 20471117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
    Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
    Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
    Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
    Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
    Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
    Kumar A; Cannon CP
    J Interv Cardiol; 2007 Dec; 20(6):447-57. PubMed ID: 18042049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.
    Sexton TR; Wallace EL; Macaulay TE; Charnigo RJ; Evangelista V; Campbell CL; Bailey AL; Smyth SS
    J Am Coll Cardiol; 2015 Jan; 65(3):306-7. PubMed ID: 25614429
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes of high dose statin loading therapy.
    Yun KH
    Int J Cardiol; 2011 Feb; 146(3):437-8. PubMed ID: 21106260
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.